Screening Libraries
| Cat. | Size | Price | Stock | |
| L20287 | 1mg/well * 15 Compounds | Inquiry | In stock | Contact Us |
| L20287 | 100uL/well (10mM solution) * 15 Compounds | Inquiry | In stock |
| manager@chemfaces.com | |
| Tel | (0086)-27-8423-7683 |
| Shelf Life | (0086)-27-84254680 |
| Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
| Container | 96 Well Format Sample |
| Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
| Shelf Life | 24 months (2-8 °) |
| Intended Use | For research use only. Not for human use. Not sell to patients |
| 1. The products in the ChemFaces screening libraries are all from plants. |
| 2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
| 3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
| 4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
| 5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
| Catalog No. | Information |
| CFN99505 | Aristolochic acid A Aristolochic acid A is a potent nephrotoxin, which strongly induced toxic damage during ovarian maturation by inhibiting Akt phosphorylation-mediated suppression of apoptosis. |
| CFN99514 | Colchicine Colchicine is a tubulin inhibitor, and a microtubule polymerization inhibitor with an IC50 of 3 nM. It prevents amyloidosis in our high-risk population and that it can prevent additional deterioration of renal function in patients with amyloidosis who have proteinuria but not the nephrotic syndrome. Colchicine has anti-mitotic activity, it can be used to treat familial mediterranean fever, and as a lead compound for the generation of potent anti-cancer drugs. |
| CFN99791 | Norcantharidin Norcantharidin has been used to treat human cancers in China since 1984, it inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation; it also enhances TIMP‑2 antitumor and anti‑vasculogenic mimicry activities in GBCs through downregulating MMP‑2 and MT1‑MMP. Norcantharidin is a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells. |
| CFN98237 | Strictosamide Strictosamide possesses antibacterial and antiviral activities, it also may have important effects on inflammation and inflammatory pain. Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity. Strictosamide has nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain. |
| CFN90213 | Telocinobufagin Telocinobufagin is a novel endogenous digitalis, it shows a reversible local anesthetic action, similar to BUPI, however, without cardiac toxicity in vitro. Telocinobufagin has antimicrobial, potential immune system regulatory effects, it could be developed as a novel immunotherapeutic agent to treat and other immune-mediated diseases, and it may become a new immunomodulatory agent in many regions. |
| CFN90237 | Gardenoside Gardenoside has hepatoprotective, pain‑relieving, and anti-mastitis effects. it may be a potential therapeutic herb against NASH by suppressed supernatant inflammatory cytokine production and intracellular NFkB activity. Gardenoside may be considered potential drug candidates that target P2X3 and P2X7 purine receptors. |
| CFN90312 | Aristololactam I Aristololactam I (AL-I), the main metabolite of aristolochic acid I (AA-I), it can lead to renal damage, the cytotoxic potency of Aristololactam I is higher than that of AA-I and that the cytotoxic effects of these molecules are mediated through the induction of apoptosis in a caspase 3-dependent pathway. |
| CFN90422 | Amphotericin B Amphotericin B is an antifungal agent. Amphotericin B can regulate inflammatory cytokines in host cells and regulate inflammatory responses in HGEC, it inhibits the A. actinomycetemcomitans-induced phosphorylation of ERK and p38 MAP kinase. Amphotericin B inhibits the A. actinomycetemcomitans-induced production of prostaglandin E2, the inhibition of the PKA signaling pathway can aid in reducing the degree of nephrotoxicity caused by Amphotericin B. Treatment with amphotericin B, particularly in combination with MCSF, increased the number of oligodendrocyte precursor cells and promoted remyelination within lesions. |
| CFN92404 | Alisol O Standard reference |
| CFN92545 | Alisol C Alisol C can improve glucose uptake in Hep G2 cells, it may be one of the therapeutic material basis in hypoglycemic activities in A. orientalis. Alisol C,16,23-oxido-alisol B and alisol O in Zexie may cause nephrotoxicity. |
